Monkeypox Testings Market Report: Market Size & Forecast 2026

The global monkeypox testing market covers diagnostic solutions used in clinical, public health, and research settings to identify orthopoxvirus and Mpox virus infections. Market valuations across recent industry assessments converge on a range of approximately USD 1.7 billion to USD 2.15 billion for the 2023-2026 period, reflecting heightened activity following the 2022 multinational outbreak. The market is expected to maintain a compound annual growth rate of roughly 4.5%, supported by sustained surveillance needs and continued testing in endemic regions of Central and West Africa.

• •Market valued at approximately USD 1.944 billion in 2026, growing from roughly USD 1.7 billion in 2023
• •Growth CAGR estimated at 4.5% across major industry forecast models
• •2022 outbreak triggered a significant spike in research output, with over 2,000 related publications recorded through 2025

The primary catalyst for market expansion has been the 2022 multinational Mpox outbreak, which elevated the disease from a regional endemic concern to a global public health priority, prompting governments and health agencies to strengthen diagnostic capacity. Ongoing surveillance programs, particularly in endemic regions of sub-Saharan Africa, create sustained demand for routine and outbreak-response testing. Additionally, technological improvements in point-of-care molecular diagnostics and the expansion of laboratory infrastructure in emerging economies are broadening the addressable market.

• •2022 multinational outbreak generated urgent demand for scaled-up diagnostic capacity and surveillance
• •Routine screening needs in endemic regions of Central and West Africa underpin baseline demand
• •Advances in point-of-care molecular testing and portable PCR platforms are expanding testing access

The market is segmented by test type, end user, and geography. By test type, nucleic acid amplification tests (NAATs), particularly real-time PCR, dominate due to their clinical accuracy and established regulatory pathways, while rapid antigen and serology-based tests serve field and resource-limited settings. End-user segments include hospitals and clinical laboratories, public health agencies, and research institutions. Geographically, North America and Europe account for the largest share of market value due to sophisticated healthcare infrastructure and high testing adoption, while sub-Saharan Africa represents a critical and growing demand center driven by endemic disease burden and increasing international health investment.

• •NAAT (PCR) testing holds the dominant segment share; rapid antigen and serology assays serve complementary use cases
• •Key end users: hospitals and clinical labs, public health agencies, and research/academic institutions
• •North America and Europe lead in market value; sub-Saharan Africa is a high-growth regional segment

Who are the notable companies in the industry?

The monkeypox testing market features a competitive landscape shaped by both large-scale diagnostic networks and specialized

• •Moderately fragmented market with diversified IVD leaders alongside infectious-disease-focused specialty producers
• •Mix of vertically integrated platform manufacturers and narrow-formula specialty assay developers
• •Primary technology routes: real-time PCR, isothermal amplification, and lateral-flow immunoassays

What are the recent trends and outlook?

Looking ahead, the market is expected to sustain steady growth as Mpox transitions toward endemic management, with periodic outbreak-response spikes contributing to demand volatility. Integration of Mpox testing panels into broader multi-pathogen respiratory and febrile-illness diagnostic panels is an emerging trend that could streamline adoption. Continued investment in vaccine R&D, reflected in the broader vaccines market's ongoing expansion, is likely to reinforce complementary demand for companion diagnostic tools. The long-term outlook remains favorable, supported by evolving WHO disease surveillance frameworks and growing emphasis on pandemic preparedness across national health systems.

• •Market expected to reach approximately USD 2.8 billion by 2033 under prevailing forecast assumptions
• •Integration of Mpox assays into multi-pathogen diagnostic panels is gaining traction among assay developers
• •WHO surveillance frameworks and pandemic preparedness investments are structural demand supports